Abstract
Decellularized extracellular matrix (dECM)-based hydrogels are widely applied to additive biomanufacturing strategies for relevant applications. The extracellular matrix components and growth factors of dECM play a crucial role in cell adhesion, growth, and differentiation. However, the generally poor mechanical properties and printability have remained as major limitations for dECM-based materials. In this study, heart-derived dECM (h-dECM) and meniscus-derived dECM (Ms-dECM) bioinks in their pristine, unmodified state supplemented with the photoinitiator of tris(2,2-bipyridyl) dichlororuthenium(II) hexahydrate and sodium persulfate, demonstrate cytocompatibility with volumetric bioprinting processes. This recently developed bioprinting modality illuminates a dynamically evolving light pattern into a rotating volume of the bioink, and thus decouples the requirement of mechanical strengths of bioprinted hydrogel constructs with printability, allowing for the fabrication of sophisticated shapes and architectures with low-concentration dECM materials that set within tens of seconds. As exemplary applications, cardiac tissues are volumetrically bioprinted using the cardiomyocyte-laden h-dECM bioink showing favorable cell proliferation, expansion, spreading, biomarker expression, and synchronized contractions; whereas the volumetrically bioprinted Ms-dECM meniscus structures embedded with human mesenchymal stem cells present appropriate chondrogenic differentiation outcomes. This study supplies expanded bioink libraries for volumetric bioprinting and broadens utilities of dECM towards tissue engineering and regenerative medicine.
Keywords: decellularized extracellular matrix (dECM), volumetric additive manufacturing, bioprinting, vat-polymerization, visible light, tissue engineering
Graphical Abstract
Decellularized extracellular matrix (dECM)-based bioinks in their pristine, unmodified state supplemented with the photoinitiator system of tris(2,2-bipyridyl) dichlororuthenium(II) hexahydrate/sodium persulfate, are demonstrated compatible with volumetric bioprinting achieving production of sophisticated tissue-like construts within tens of seconds. As exemplary applications, volumetrically bioprinted heart-dECM cardiac and meniscus-dECM structures both present appropriate functions, suggesting expanded bioink libraries for volumetric bioprinting with dECM biomaterials.
Three-dimensional (3D) bioprinting technologies are broadly applied to building living tissue constructs for applications in regenerative engineering, including transplantation, drug screening, and disease modeling.[1–5] However, current additive biomanufacturing technologies, including but not limited to extrusion-based bioprinting,[6] stereolithographic bioprinting,[7] and digital light processing (DLP) bioprinting,[8, 9] all fabricate 3D constructs in a point-by-point or layer-by-layer fashion.[8, 10] This feature presents certain challenges when producing sophisticated hydrogel structures that are oftentimes mechanically weak, especially those that contain freeform architectures. In addition, for bioprinting with cell-laden bioinks, these conventional methods also are limited because of the considerable fabrication time required, which positively correlates with the size of the tissue constructs.[11–13] Thus, to overcome these limitations of conventional additive biomanufacturing techniques, new methodologies are needed to improve tissue bioprinting capacities.
The volumetric additive manufacturing (VAM) technology prints the entire object at once, thus developed to address many of the abovementioned challenges.[14] Specifically, VAM illuminates dynamically evolving light patterns into specific portions of the volume of a photoresin contained in a transparent vial, which is synergistically rotated perpendicular to the direction of incident light. As such, the photoresin is only crosslinked at desired volumes where sufficient light doses are accumulated after angular exposures with the computed planar patterns,[15] leading to solidification of the target object with optimized shape fidelity. Briefly, in contrast to conventional 3D bioprinting technologies with still slower printing speeds and sometimes insufficient surface qualities,[16] VAM can fabricate objects in a single pass with a lower concentration of bioinks, enabling much faster production rates of items, particularly those with complex geometries. These advantages of VAM on creating detailed, complicated structures make it promising for biomedical applications, such as fabricating soft tissues or organs. Although a few photoresins have been reported for VAM (or termed volumetric bioprinting when it comes to printing cell-laden bioinks),[10, 17] such as silica glass,[18] acrylate polymers,[14, 19] gelatin methacryloyl (GelMA),[17] gelatin-norbornene (Gel-NB),[20] and silk fibroin and sericin,[21] there remains a significant demand to develop additional bioinks to facilitate expanded applications for this new technology.
Decellularized extracellular matrices (dECM) as a class of biomaterials directly extracted from native tissues, have been widely used for tissue fabrication. dECM have similar components and compositions to their source tissues, enabling better recapitulation of intricate and cytocompatible microenvironments contributing to improved cell functionality and tissue morphogenesis than some of the conventional bioinks.[22, 23] In addition, the dECM technology, after decades of advancement, can now be conveniently derived from different organs and tissues with mature protocols, leading to broadened and consistent supplies and thus expanded applications. Indeed, a number of tissues including but not limited to skin, bone, kidney, heart, cornea, liver, and vasculature,[22, 24–27] have been fabricated using dECM by different additive (bio)manufacturing methods indicating the potential of this source of biomaterials.[28–32] Nevertheless, dECM bioinks are usually weak in mechanical properties and thus exhibit poor printability when used alone at low concentrations, which dramatically reduces the practicality of using dECM in bioprinting of sophisticated tissue structures. Although some strategies such as physical supporting,[28, 33, 34] hybrid bioinks,[35] and chemical conjugation[36–38] were introduced to increase print fidelity and stability of dECM, limitations remain in terms of maintaining native bioactivities of pristine dECM in their unmodified state.[39]
A visible light-induced crosslinking approach was recently proposed and utilizes pristine dECM (without chemical conjugation or mixing with any other biomaterials) by taking advantage of a newer photoinitiator system, tris(2,2-bipyridyl)dichlororuthenium(II) hexahydrate/sodium persulfate (Ru/SPS).[22, 40] For both extrusion-based bioprinting or DLP-based bioprinting, the dECM bioinks could be polymerized via a di-tyrosine crosslinking mechanism. Despite the success in efficient photocrosslinking during or after bioprinting, these bioprinting modalities share the same limitations as discussed above, i.e., being relatively slow processes and oftentimes requiring strong mechanical properties of the bioinks for creating sophisticated volumetric tissue patterns.
In this study, we introduce the compatibility of pristine, unmodified heart-derived dECM (h-dECM) and meniscus-derived dECM (Ms-dECM) combined with Ru/SPS as a new class of bioinks for volumetric bioprinting. Generally, compared with privous 3D bioprinting work with dECM, our work introduces several unique aspects: i) We utilize unmodified dECMs mixed with a photoinitiator as our bioinks without needing additional biomaterial types. This approach creates microenvironments more closely resembling natural tissues than hybrid bioinks. ii) The VAM technology has allowed us to employ a lower concentration of dECMs at 1% compared to oftentimes the higher dECM concentrations required before, which not only conserves materials but more importantly, also exhibits superior biological compatibility. iii) Our study demonstrates the rapid fabrication speeds enabled by VAM, with the entire process taking only approximately 30-45 s for both h-dECM and Ms-dECM.
To highlight the advantages of VAM, we aimed to print both hollow and solid tissue structures, with the heart representing a hollow structure and the meniscus representing a solid one. As noted, our photoinitiator system used, Ru/SPS, plays a crucial role in the process by oxidizing aromatic residues, including tyrosine. The oxidized tyrosine groups, activated by Ru/SPS, are then converted into tyrosyl free radicals, which subsequently form covalent di-tyrosine bonds with nearby tyrosine moieties.[41] Furthermore, to achieve higher crosslinking efficiency, we sought to employ dECM types with a higher content of tyrosine. In comparison to other organs, such as the brain, h-dECM and Ms-dECM contain higher proportions of collagen, which is rich in tyrosine.[28, 41] Therefore, choosing h-dECM and Ms-dECM for proof-of-concept demonstrations has allowed us to attain more rapid and better printing processes. However, the technology can be easily expanded to other dECM types in the future with further optimizations of the printing parameters. Again in general, dECM types rich in collagen, such as those from skin and lung tissues, other than the ones used here, are likely to be more readily adaptable to the VAM technology; in contrast, tissues with lower collagen contents, such as brain and kidney cortex, may pose challenges when integrating with the Ru/SPS crosslinking system without functionalization (Table S1).
h-dECM was derived from the left ventricle of porcine heart (Figure 1A, Figure S1A), while Ms-dECM was obtained from porcine meniscus (Figure 1A, Figure S1B). Both types of dECM bioinks contain abundant tyrosine residue-carrying protein components that form di-tyrosine crosslinks[28, 41] after photoactivation in the presence of the Ru/SPS system (Figure 1B). For exemplary demonstrations of biomedical applications of our custom-built volumetric bioprinter (Figure 1C), rat cardiac myocyte (rCM)-laden h-dECM bioinks and human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM)-laden h-dECM bioinks, and human mesenchymal stem cell (hMSC)-laden Ms-dECM bioinks were prepared (Figure 1B) for bioprinting of living cardiac and meniscus constructs, respectively (Figure 1C). The cytocompatible microenvironments of dECM as well as the rapid fabrication speeds (~45 s for h-dECM and ~30 s for Ms-dECM) enabled by volumetric bioprinting ensured desirable functions of the embedded cells during bioprinting and post-bioprinting culture. It is believed that the volumetric bioprinting system in conjunction with light-activated dECM bioinks in their pristine, unmodified state has enormous potential for engineering hydrogel structures and tissue constructs for expanded applications in biomedicine.
Figure 1.
Schematics showing the dECM (bio)ink preparation and VAM processes. A) Decellularization of porcine heart and meniscus for obtaining h-dECM and Ms-dECM. B) Preparation of cell-laden bioinks and the photocrosslinking mechanism of dECM bioinks. C) VAM process and the customized VAM system, which mainly includes a projector, a vial-rotation motor, and a (bio)ink-containing vial. h-dECM: heart-derived decellularized extracellular matrix; Ms-dECM: meniscus-derived decellularized extracellular matrix; VAM: volumetric additive manufacturing; Ru: tris(2,2-bipyridyl)dichlororuthenium(II) hexahydrate; SPS: sodium persulfate.
For light-activated VAM with Ru/SPS, the wavelength of the projector light at 525 nm would perform betters than UV-blue light.[21, 42] The absorbance at 525 nm of different concentrations of h-dECM and Ms-dECM indicated that h-dECM had a higher absorbance than Ms-dECM (Figure S2A, B), and dECM at high concentrations showed higher absorbance values than that at low concentrations (Figure S2C). According to numerous previous studies, the ratio of Ru to SPS at 1 to 10 seems to be the best working ratio for photocrosslinking under many scenarios.[21, 22, 43] The mixing of dECM with varying concentrations of Ru/SPS resulted in a significant increase in absorbance values, with a gradual rise observed as the concentration of Ru/SPS was increased from 0/0 mM to 2/20 mM (Figure S2D). Crosslinkability test was performed by photocrosslinking different formulations of h-dECM and Ms-dECM (bio)inks with 525 nm of light and 3 mW cm−2 of light intensity (Figure S3A, B). The photocrosslinkability maps (Figure S3C) clearly indicated that, i) there was insufficient material for crosslinking when the concentration of dECM was below 0.5%, and ii) the concentration of Ru/SPS below 0.25/2.5 mM could not support the photocrosslinking process of dECM at any concentration.
After printing with the photocrosslinkable formulations of the dECM (bio)inks, printability maps were further refined (Figure 2A, B). The 2% h-dECM (bio)ink or 1.5% Ms-dECM (bio)ink showed poor printability as they required more photoinitiator to form the di-tyrosine networks, while high concentrations of Ru/SPS (over 1/10 mM) dramatically reduced the penetration depth of the incident light (Tables S2, S3), which also impacted print shape fidelity.[21, 22] Of interest, 1% h-dECM and 1% Ms-dECM combined with 0.25/2.5-mM or 0.5/5-mM Ru/SPS presented better printabilities than the 0.5% h-dECM and 0.5% Ms-dECM (bio)inks. Subsequently, printing efficiencies were determined by comparing the printing times of all printable dECM (bio)ink formulations (Figure 2C, D). Remarkably, all the printing times were less than 90 s, generally faster than the traditional DLP process, which typically requires a few to tens of minutes to produce cubic constructs of the same size.[42] Furthermore, 1% h-dECM and 1% Ms-dECM with different concentration of Ru/SPS were printed faster than 0.5% h-dECM and 0.5% Ms-dECM. To visually compare the shape fidelities of 3D constructs volumetrically printed by the different formulations of the (bio)inks, photographs of the printed cubic structures were collected (Figure 2E, F, Figure S4A, B). The ratios of height to width (Figure 2G, H) and the ratios of height to length (Figure S4C, D) of the cubes were calculated to quantify the printing fidelities, confirming again that 1% h-dECM and 1% Ms-dECM mixed with 0.25/2.5-mM or 0.5/5-mM Ru/SPS had favorable printability performances than other groups.
Figure 2.
Printing performance of VAM with dECM (bio)inks. A, B) Printability maps of (A) h-dECM (bio)ink and (B) Ms-dECM (bio)ink with different formulations. √: printable; O: printable but shape not good; X: non-printable. C, D) Heat maps of printing times for 3D cubic constructs from (C) h-dECM and (D) Ms-dECM with different formulations. E, F) Photographs of 3D cubic construct printed using (E) 1% h-dECM (bio)ink and (F) 1% Ms-dECM (bio)ink with different concentrations of Ru/SPS. G, H) Quantified ratios of the height to width of the 3D cubic construct printed using (G) h-dECM (bio)ink and (H) Ms-dECM (bio)ink with different concentrations of Ru/SPS. I) CAD models and photographs of printed objects using 1% h-dECM with 0.5-mM Ru/5-mM SPS (light intensity: 3 mW cm−2). The heart construct was printed in 45 s, and the ear construct was printed in 30 s. J) CAD models and photographs of printed objects using 1% h-dECM with 0.25-mM Ru/2.5-mM SPS (light intensity: 3 mW cm−2). The cubic frame construct was printed in 60 s and the channeled cube construct was printed in 60 s. K) CAD model and photograph of printed object using 1% Ms-dECM with 0.5-mM Ru/5-mM SPS (light intensity: 3 mW cm−2). The meniscus construct was printed in 30 s. L) CAD models and photographs of printed objects using 1% Ms-dECM with 0.25-mM Ru/2.5-mM SPS (light intensity: 3 mW cm−2). The bone construct was printed in 45 s, and the screw structure was printed in 30 s. M) Schematic showing the effect of concentration of Ru/SPS and concentration of dECM on printing resolution. N) Quantified penetration depths of h-dECM with different formulations. O(i) and (ii)) CAD model of the solid bar, where the thicknesses of the threads were from 1 μm to 101 μm. O(iii) and (iv)) Microscopic images of the printed solid bars from 1% h-dECM (printing time: 30 s; light intensity: 3 mW cm−2) and 1% Ms-dECM (printing time: 35 s; light intensity: 3 mW cm−2) at 0.5-mM Ru/5-mM SPS. P(i) and (ii)) CAD model of the radially arranged array of cubes. P(iii) and (iv)) Microscopic images of the printed cube arrays from 1% h-dECM (printing time: 30 s; light intensity: 3 mW cm−2) and 1% Ms-dECM (printing time: 35 s; light intensity: 3 mW cm−2) at 0.5-mM Ru/5-mM SPS. Q) Quantified resolutions in X/Y and Z directions of the printed constructs. Statistical significances are expressed as *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001 by two-way ANOVA with Tukey’s post hoc test; n = 10, ns = not significant. dECM: decellularized extracellular matrix; VAM: volumetric additive manufacturing; h-dECM: heart-derived decellularized extracellular matrix; Ms-dECM: meniscus-derived decellularized extracellular matrix; Ru: tris(2,2-bipyridyl)dichlororuthenium(II) hexahydrate; SPS: sodium persulfate.
These data suggested that the printing shape fidelity using volumetric printing heavily relied on the concentrations of the dECM and the photoinitiator (Ru/SPS), consistent with previous reports on VAM using different (bio)ink systems.[18, 20, 21] Compared with other conventional additive manufacturing methods such as DLP and extrusion,[22, 24, 44, 45] the VAM process works well with significantly lower concentrations of dECM (Table S4), reducing (bio)ink-preparation challenges as well as allowing lower stiffness of the constructs to be produced. Furthermore, even at a low concentration, the dECM-based bioinks naturally possessed relatively high viscosity values due to their complex macromolecular interactions, which includes various extracellular matrix components.[23] This inherent viscosity behavior plays a crucial role in the VAM printing process, which generally requires thermo-reversible crosslinking or sufficient viscosities of the bioinks used. All these features are beneficial towards expanded applications of dECM biomaterials towards biomedicine.
Using the optimized formulations of dECM-based (bio)inks that showed good printing fidelities, we subsequently explored the ability to produce additional constructs with more sophisticated architectures. For example, a human heart structure containing the hollow aorta and a human ear structure (Figure 2I), as well as a Chinese temple structure and a screw structure (Figure S5A), were printed with 1% h-dECM combined with 0.25/2.5-mM Ru/SPS. The heart and ear constructs were printed in approximately 45 s, while the screw and the temple were printed in ~30 s. Similarly, with 0.5/5-mM Ru/SPS, the 1% h-dECM (bio)ink was volumetrically printed into sophisticated 3D geometries, such as a cubic frame and a cube with a hollow channel (Figure 2J), both at ~45 s. Alternatively, a human meniscus structure (~30 s; Figure 2K) and a human ear structure (~ 45 s; Figure S5B) were printed using 1% Ms-dECM with 0.25/2.5-mM Ru/SPS. A human femur-like structure and a screw structure (Figure 2L) were further printed using 1% Ms-dECM containing 0.5/5-mM Ru/SPS. The good VAM performance of these optimized dECM (bio)inks illustrated the potential wide utility. Intriguingly, even for these sophisticated patterns, the printing times still only ranged from 30 s to 45 s, indicating that the printing efficiency was not significantly impacted by the complexity of the structure made. Compared with the same structures such as the heart,[34] ear,[46] and screw[47] printed using other traditional additive manufacturing methods, the VAM process reduced the exposure time of the material to the external environment (from minutes/tens of minutes to tens of seconds), which should reduce the stress on embedded cells when cell-laden bioprinting is utilized.[10]
Due to the limitation of the penetration depth, the maximum size we could print with our dECM-VAM coupled with Ru/SPS system was approximately 10 mm for the objects’ diameter, substantially smaller than the actual dimensions of target organs such as the human heart or meniscus. The use of different biomaterial and photoinitiator systems (Table S5) in other VAM studies had shown higher penetration depths and thus larger sizes achievable. Nevertheless, some of those materials systems, such as poly(ethylene glycol)-diacrylate would inevitably compromise cellular activities in most cases, bringing a significant limitation for biomedical applications. Furthermore, it is important to note that size limitations can also vary significantly between different bioprinting technologies (Table S5). Some slower but more traditional printing methods, such as DLP and extrusion, may offer the ability to produce significantly larger constructs due to their sequential point-by-point or layer-by-layer approach. However, these methods often come at the cost of increased printing time and may face challenges in achieving the same level of spatial complexities that are demonstrated with volumetric bioprinting. Additionally, those technologies impose more stringent demands on material properties, such as concentration and mechanics, which then require to apply modifications to the biomaterials or adopt hybrid biomaterial systems. Notably, with natural biomaterials such as dECM utilized in our study, other technologies so far have not demonstrated the ability generating high-fidelity structures with good complexities at low concentrations, indicating the unique advantage of the volumetric bioprinting approach adopted here despite the same size limitation.
Resolution is another important parameter for volumetric bioprinting. With the known resolution (1140×912 pixels) of the projector, the printing resolution of the dECM-based (bio)inks was dramatically influenced by the light penetration depth, which was closely correlated with the concentrations of both dECM and Ru/SPS. The high concentration of dECM or Ru/SPS blocks light dose coming through the (bio)ink vial, which would then cause reduced penetration depth (Figure 2M). Specifically, printing using (bio)inks with poor penetration depths resulted in material crosslinking along the walls of the vial, which could change the light path and impede the crosslinking process within the central regions (Figure S6). The penetration depth analyses of 525-nm light for 1% Ms-dECM (Figure 2N), for example, indicated that the Ms-(bio)ink mixed with 0.25/2.5-mM Ru/SPS exhibited a deeper penetration depth (~12 mm), which was larger than the radius of glass vial (6 mm) used in the process; a similar situation was observed with 0.5/5-mM Ru/SPS. In comparison, all the other formulations of the (bio)ink and Ru/SPS combinations showed poor penetration depths (<6 mm; Figure S7), unsuitable for VAM in our setup.
To quantify the resolutions of h-dECM and Ms-dECM, two custom-designed patterns, i.e., a solid rod with bars (Figure 2O(i), (ii)) and a radially arranged array of cubes with different diameters (Figure 2P(i), (ii)) were printed using 1% h-dECM and Ms-dECM supplemented with 0.5/5-mM Ru/SPS. For the axial resolution on the vertical (Z) direction, the photographs of the printed solid rods (~25 s for h-dECM and ~30 s for Ms-dECM) showed that the size of smallest bar thickness of the h-dECM rod was ~79 μm, while that of Ms-dECM was ~133 μm (Figure 2O(iii), (iv)), suggesting that h-dECM led to a higher printing resolution in the Z-axial direction than Ms-dECM under similar conditions. Furthermore, resolutions in the X-Y plane were evaluated by printing a radially arranged array of cubes with different diameters. The smallest diameter of the h-dECM cubes was ~137 μm (Figure 2P(iii)), which was also better than the smallest diameter (~207 μm) printed with Ms-dECM (Figure 2P(iv)). For comparison, the pattern of solid rod with bars was also printed using h-dECM and Ms-dECM with concentrations of Ru/SPS at 0.25/2.5 mM. However, the resulting micrographs (Figure S8) failed to display discernible bars, indicating a substantial reduction in printing resolution under these conditions, which warrants further investigations of improvements.
Accordingly, the results of the resolution tests (Figure 2Q) suggested that the h-dECM resulted in higher resolutions in all directions (X, Y, and Z) than the Ms-dECM when volumetrically printed. Since the prints were conducted under the same concentrations of Ru/SPS, such a difference in resolution could be primarily influenced by the variations in the dECM components. Molecular weight analyses by sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) for h-dECM and Ms-dECM indicated the presence of three distinct bands, with the strongest band observed at approximately 160 kDa and two other weaker visible bands at 260 kDa and 35-40 kDa (Figure S9), consistent with literature.[48] Previous reports indicated that collagen is the primary component of these dECM biomaterials, while Ms-dECM also contains abundent fibronectin and thrombospondin,[49] and h-dECM has more fibronectin and elastin.[50] These different protein components and the larger cartilage fibers[51] in Ms-dECM might cause more light scattering during printing, leading to lower resolution than for h-dECM. Overall, the printing performance and resolution were related to a combination of factors, including printing time, dECM concentration, Ru/SPS concentrations, as well as the intrinsic characteristics of the dECM, which could be inferred when expanding VAM to other (bio)inks in the future.
Mechanically, the range of compressive moduli of dECM hydrogels prepared with different crosslinking systems have been reported in the range of 0.18 to 3.0 kPa.[52, 53] To evaluate the mechanical properties of dECM photocrosslinked with Ru/SPS, cylindrical constructs with a diameter at 1 cm and a thickness at 5 mm (Figure S10A) were printed (30 s) with different formulations of dECM (bio)inks for compression tests (Figure S10B). The moduli were measured at 10.9 ± 4.5 kPa for h-dECM printed with 0.25/2.5-mM Ru/SPS, and 28.4 ± 2.5 kPa at 0.5/5-mM Ru/SPS; for the cylinders printed using Ms-dECM, the moduli were lower than those for h-dECM constructs, at 4.1 ± 0.6 kPa for 0.25/2.5-mM Ru/SPS and 14.3 ± 1.2 kPa for 0.5/5-mM Ru/SPS (Figure S11). Notably, our volumetrically printed dECM objects had higher moduli than previously reported prints of the dECM without Ru/SPS.[54] This observation could be attributed to the fact that di-tyrosine crosslinks dramatically improve the mechanical properties of dECM hydrogels compared with thermally crosslinked dECM hydrogels, up to approximately 3.0 kPa.[22, 55] Nevertheless, the moduli of our volumetrically printed dECM materials were still much lower than DLP-printed constructs previously reported despite the use of Ru/SPS as the photoinitiator system,[22] given the feasibility to use much smaller dECM concentrations as low as 1% in our setup.
Scanning electron microscopy (SEM) was utilized to examine the morphologies of VAM-printed dECM constructs after dehydration. Compared with the fibrous morphologies with dense and randomly oriented collagen in thermally crosslinked Ms-dECM hydrogel,[56] the cylinders volumetrically printed with Ms-dECM and Ru/SPS showed porous structures. In comparison, VAM-printed h-dECM constructs had relatively denser matrices without the presence of noticeable pores, at the same concentration of 1% used (Figure S12). These results partially explained why the mechanical properties of printed h-dECM constructs were higher than those printed with Ms-dECM with the same concentrations of dECM/photoinitiator. However, it should be noted that SEM images do not necessarily reflect the actual pore sizes of the dECM constructs in their hydrated state although the trends are maintained.
The in vitro degradation profiles of the volumetrically printed 1% h-dECM and 1% Ms-dECM cylinders (with 0.25/2.5-mM Ru/SPS) were subsequently evaluated in phosphate-buffered saline (PBS), collagenase IV PBS solution, and α-chymotrypsin PBS solution at 37 °C for up to 28 days (Figure S13). During the initial 2 days of the evaluations in PBS, the samples exhibited a slight swelling behavior, resulting in an approximate 5% increase in their wet masses. Subsequently, the masses of the samples began to gradually decrease. Notably, the 1% h-dECM-printed samples experienced a reduction in mass to 71.5%, while the 1% Ms-dECM-printed cylinders reached a mass of 84.3% after 28 days (Figure S13A), suggesting that the volumetrically printed 1% Ms-dECM samples exhibited favorable stability under physiological conditions. In contrast, all constructs degraded rapidly (in 3 h) when incubated with collagenase IV solution, since the main component of both dECM types is collagen. In the presence of α-chymotrypsin, the Ms-dECM constructs presented better stability (~24 h) than those with h-dECM, which were digested within 12 h. These results demonstrated that the degradation profiles of VAM-printed dECM constructs were intimately related to the crosslinking densities of the prints, the dECM types, as well as the microenvironments in which they were exposed.
To evaluate cell-ladened dECM bioinks, three sophisticated structures were volumetrically bioprinted (Figure 3A) with 1×106 mL−1 of NIH/3T3 fibroblasts, an ear-like structure (45 s of bioprinting time, 1% Ms-dEM with 0.25/2.5-mM Ru/SPS), a heart-like structure (45 s of bioprinting time, 1% h-dECM with 0.25/2.5-mM Ru/SPS), and a screw structure (30 s of bioprinting time, 1% Ms-dECM with 0.5/5-mM Ru/SPS). These structures were generated with good shape fidelity (Figure 3B) indicating that the printing performance was not significantly influenced by the encapsulated cells within the dECM.
Figure 3.
Cytocompatibility of dECM bioinks and characterizations of cardiac tissues volumetrically bioprinted using the rCM- or hiPSC-CM-laden h-dECM bioink. A) Schematic showing the process of volumetric bioprinting with cell-laden d-ECM bioinks. B) CAD models and microscopic images of the structures volumetrically bioprinted with NIH/3T3 fibroblast-laden d-ECM bioinks. The ear structure was bioprinted with 1% Ms-dECM and 0.25/2.5-mM Ru/SPS in 30 s (cells was stained with red CellTracker). The heart structure was bioprinted with 1% h-dECM and 0.25/2.5-mM Ru/SPS in 45 s (cells were stained with blue CellTracker). The screw structure was bioprinted with 1% Ms-dECM and 0.25/2.5-mM Ru/SPS in 30 s (cells was stained with green CellTracker). C, D) Micrographs showing live/dead staining of NIH/3T3 fibroblasts bioprinted within (C) 1% h-dECM constructs and (D) 1% Ms-dECM constructs at different concentrations of Ru/SPS for 7 days. E, F) Metabolic activity profiles of NIH/3T3 fibroblast bioprinted within (E) 1% h-dECM constructs and (F) 1% Ms-dECM constructs at different concentrations of Ru/SPS for 7 days. G, H) F-actin staining micrographs of NIH/3T3 fibroblasts grown within bioprinted (G) 1% h-dECM and (H)1% Ms-dECM constructs at different concentrations of Ru/SPS for 7 dyas. I) Schematic showing the volumetric bioprinting process of the heart-like structure and the process of rCMs spreading. J, K) (J) Quantified cell viability values and (K) metabolic activity profiles of rCMs grown in the heart-like constructs bioprinted using 1% h-dECM at different concentrations of Ru/SPS for 14 days. L, M) (L) Micrographs of F-actin staining and (M) quantified lengths of rCMs spread in the heart-like constructs bioprinted using 1% h-dECM at different concentrations of Ru/SPS for 14 days. N, O) Micrographs showing (N) brightfield and (O) fluorescent immunostaining of hiPSC-CMs both on the surface and encapsulated in the heart-like constructs bioprinted using 1% h-dECM and 0.25/2.5-mM Ru/SPS reaching a stretching morphology and expressing sarcomeric-α-actinin after culturing for 10 days. Statistical significances are expressed as *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001 by two-way ANOVA with Tukey’s post hoc test. In figures (D, F, K, and L), n = 3; in figures (H, J, and N), n = 10; ns = not significant. dECM: decellularized extracellular matrix; VAM: volumetric additive manufacturing; Ru: ruthenium (II) hexahydrate; SPS: sodium persulfate; h-dECM: heart-derived decellularized extracellular matrix; Ms-dECM: meniscus-derived decellularized extracellular matrix; Ru: tris(2,2-bipyridyl)dichlororuthenium(II) hexahydrate; SPS: sodium persulfate; rCMs: rat cardiac myocytes; hiPSC-CMs: human induced pluripotent stem cell-derived cardiomyocytes.
Viabilities of the fibroblasts encapsulated in different formulations of dECM bioinks were assessed by live/dead assay for up to 14 days of culture (Figure 3C, D, Figure S15A, B), indicating that cells embedded in all bioink formulations evaluated remained viable. However, viabilities of cells embedded in both 1% h-dECM and 1% Ms-dECM bioprinted with 0.25/2.5-mM Ru/SPS were higher than those for the cells in dECM bioprinted with 0.5/5-mM Ru/SPS (Figure S16A, B), likely due to the reduced phototoxcity when a lower concentration of photoinitiator was used. Additionally, the cell proliferation rates and metabolic activities within both 1% h-dECM and 1% Ms-dECM with 0.25/2.5-mM Ru/SPS increased over 14 days, while the metabolic activities of cells with 0.5/5-mM Ru/SPS reminded steady in the late stage, indicating that the cells stopped proliferating or reduced their metabolic activities after 7 days (Figure 3E, F).
Similarly, when examining the morphologies of the cells, the embedded fibroblasts only spread in the 1% h-dECM and 1% Ms-dECM volumetrically bioprinted with 0.25/2.5-mM Ru/SPS, cultured for up to 14 days (Figure 3G, H, Figure S17A, B). Specifically, the size of the cells in the dECM constructs produced in the presence of 0.5/5-mM Ru/SPS did not significantly change over the culture period (15.06 ± 1.63 µm), whereas the length of the cells in dECM bioprinted with 0.25/2.5-mM Ru/SPS increased in the first 7 days (up to 85.12 ± 13.17 µm) and remained stable thereafter (Figure S18). The overall favorable cytocompatibility of dECM as exhibited in these results was consistent with previous reports suggesting low crosslinking densities for light-activated bioprinting are well-suited for culturing cells of soft tissue-origin.[57–59]
Furthermore, Ru/SPS is generally considered to be less cytotoxic than some other photoinitiators.[40, 43] However, its potential cytotoxicity can still affect the cytocompatibility of bioprinted dECM constructs when cells are exposed to high concentrations of Ru/SPS for longer periods. Compared with the 1/10-mM[43] and 2/20-mM[22] Ru/SPS used in some previous studies, the 0.25/2.5-mM or 0.5/5-mM Ru/SPS adopted in most of our work is significant lower, indicating a reduced cytotoxic effect. In addition, we conducted further analyses on the Ru/SPS-release from the volumetrically printed structures. Photographs clearly illustrated color changes in the samples when they were immersed in PBS at 37 °C over a 24-h period (Figure S19A). By measuring the optical absorbance values of the buffer, we determined that Ru/SPS was released approximately 55.3% from h-dECM and 49.4% from Ms-dECM within the first 30 min after printing, and eventually reaching to a ~100% release for h-dECM and ~94% for Ms-dECM (Figure S19B). Accordingly, the Ru/SPS photoinitiator used in our approach at low concentrations and was rapidly released from the constructs may bring advantages for future biomedical applications.
Finally, to demonstrate that tissue-specific constructs could be fabricated via volumetric bioprinting of dECM bioinks, a human heart-like structure was created using rCM-laden h-dECM bioink containing different concentrations of Ru/SPS (0.25/2.5 mM and 0.5/5 mM; Figure 3I). The viability of rMCs was evaluated using the live/dead assay (Figure S20). It was observed that the rCMs encapsulated in the cardiac tissue constructs volumetrically bioprinted with 0.25/2.5-mM Ru/SPS remained >95% viable even after 14 days of culture; in contrast, the bioprinted constructs with 0.5/5-mM Ru/SPS only showed approximately 50-75% viability for the cells during the same culture period (Figure 3J). The cellular metabolic activities of rCMs encapsulated in the cardiac constructs bioprinted with 0.25/2.5-mM Ru/SPS were also significantly higher than cells in the other group (Figure 3K). These cellular results on rCMs aligned well with those on NIH/3T3 fibroblasts, confirming that our h-dECM bioink formulations might be generally suitable for soft tissue engineering using volumetric bioprinting.
Moreover, F-actin staining indicated that over 95% rCMs spread in the cardiac structures volumetrically bioprinted with 0.25/2.5-mM Ru/SPS after 7 days of culture, while the cells still only partially (30-40%) spread in those bioprinted with 0.5/5-mM Ru/SPS during the same culture period (Figure 3L, M, Figure S21), different from the observations with fibroblasts where no cells spread in the denser matrices. As h-dECM readily captures the matrix components that are found in the native cardiac tissue, such as relevant proteins, glycosaminoglycans, and proteoglycans,[60] it could provide cells derived from the same tissue source with an appropriate microenvironment to support cell viability and spreading.
To further demonstrate the functions of the bioprinted heart-like constructs with h-dECM, samples were prepared using 1% h-dECM and 0.25/2.5-mM Ru/SPS, integrated with the human iPSC-derived cardiomyocytes (hiPSC-CMs). The brightfield microscopic images (Figure 3N) revealed the morphologies of hiPSC-CMs, showing cellular spreading both on the surfaces and within the matrix following a 10-day culturing period. Notably, the spontaneous beating movements of hiPSC-CMs were observed cells in both configurations as well, from day 5 of bioprinting. Videos S1 and S2 respectively show the synchronized contractions of hiPSC-CMs recorded on day 10 for cells on the surface and encapsulated within matrix of the samples. Similarly, the immunofluorescence staining of hiPSC-CMs for sarcomeric-α-actinin on both seeded and encapsulated samples on day 10 demonstrated the development of sarcomere structures, indicating the structural maturation of hiPSC-CMs under both conditions (Figure 3O). Sarcomeric-α-actinin is the key protein in the structure and function of cardiomyocytes and plays a crucial role in the organization of the contractile apparatus in muscle cells, particularly in the sarcomere.[61] As such, this cardiac model not only offers a novel platform for the study of heart-related diseases but also holds potential as a strategic approach in cardiac tissue engineering and transplantation applications in the future.
A step further in illustrating the potential of different types of dECM used towards biomedical applications, meniscus constructs laden with hMSCs were also volumetrically bioprinted using 1% Ms-dECM containing 0.25/2.5-mM or 0.5/5-mM Ru/SPS. hMSCs sustained high viability values at ~95% across 14 days of culture (Figure 4A, B), validating the favorable cytocompatibility of Ms-dECM with the cells. Similar to the results obtained from the other cell types, the cellular metabolic activities of hMSCs encapsulated in the meniscus constructs bioprinted with 0.25/2.5-mM Ru/SPS were almost twice as high as the cells in the denser constructs, by 14 days (Figure 4C). Interestingly, extensive spreading (~100%) of hMSCs was observed in both meniscus constructs irrespective of the crosslinking density (Figure 4D, Figure S22), again suggesting tissue-specificity of the dECM bioinks in directing cellular behavior matching the origins of the biomaterial.
Figure 4.
Characterizations of meniscus tissues volumetrically bioprinted using the hMSC-ladened Ms-dECM bioink. A-C) (A) Micrographs of live/dead staining, as well as quantified (B) cell viability values and (C) proliferation profiles of hMSCs grown in the meniscus constructs bioprinted using 1% Ms-dECM at different concentrations of Ru/SPS. D) Micrographs showing F-actin staining of hMSCs spread in the bioprinted meniscus constructs. E) Micrographs showing F-actin staining of hMSCs in the meniscus constructs bioprinted using 1% Ms-dECM and 0.25/2.5-mM Ru/SPS over 3 weeks of differentiation. F) Micrographs showing immunostaining of hMSCs in the meniscus constructs bioprinted using 1% Ms-dECM and 0.25/2.5-mM Ru/SPS expressing different levels of collagen and aggrecan over 3 weeks of differentiation. G) Quantified expression levels of representative genes indicating chondrogenic differentiation status in 3 weeks. H) Low-magnification micrograph showing F-actin staining of hMSC-ladened meniscus tissue printed using 1% Ms-dECM and 0.25/2.5-mM Ru at 3 weeks of differentiation. Inset shows confocal image of the high-density differentiated chondrocytes. I) Histology images of H&E, Masson’s trichrome, and Sirius red staining for the bioprinted meniscus constructs printed using 1% Ms-dECM and 0.25/2.5-mM Ru containing hMSCs after 3 weeks of chondrogenic differentiation. Statistical significances are expressed as *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001 by two-way ANOVA with Tukey’s post hoc test; n = 3, ns = not significant. dECM: decellularized extracellular matrix; Ru: tris(2,2-bipyridyl)dichlororuthenium(II) hexahydrate; SPS: sodium persulfate. hMSCs: human mesenchymal stem cells; Ms-dECM: meniscus-derived decellularized extracellular matrix.
We subsequently evaluated functional performance of the meniscus tissues volumetrically bioprinted using 1% Ms-dECM in combination with 0.25/2.5-mM Ru/SPS. The constructs were transferred to and cultured in chondrogenic differentiation medium for 3 weeks after 2 weeks of initial culture in proliferation medium. F-actin staining of the differentiated chondrocytes further indicated that the cells not only expanded in cell lengths but also in width (Figure 4E), consistent with previous reports.[28, 55] Immunostaining of the menisci showed that the expression of collagen and aggrecan improved in the 3-week period (Figure 4F), indicating successful differentiation of hMSCs into the chondrocyte lineage. The expression of chondrogenesis-related genes obtained by quantitative polymerase chain reaction (qPCR), including aggrecan (ACAN), cartilage oligomeric matrix protein (COMP), collagen type I alpha 1 chain (COL1α1), elastin (ELN), and type X collagen (COL10A1) (Figure 4G), also validated the immunostaining results. Specifically, the expression of COL10A1 and ELN increased significantly during the 3 weeks, while the expression of COL1A1 also increased post-differentiation, although not to a statistically significant degree. In an image revealing the morphology of the entire meniscus structure at 5 weeks of culture (Figure 4H), the embedded, expanded, and differentiated hMSCs were evident (Figure S23), and the shape of the meniscus did not change, indicating the stability of the cell-laden VAM-bioprinted tissue-like constructs.
Finally, to demonstrate the general morphology and the production of glycosaminoglycans (GAGs) of the hMSCs during chondrogenic differentiation in the bioprinted tissues, the samples were histologically stained with hematoxylin and eosin (H&E), Masson’s trichrome, and Sirius red (Figure 4I). Compared with the undifferentiated samples (week 0), H&E-staining images revealed the presence of typical triangular and ovoid-shaped chondrocytes,[62] which filled the normal-appearing lacunae of the constructs over time. Masson’s trichrome and Sirius red staining revealed that the cartilage extracellular matrix components, including collagen and GAGs,[63, 64] were present in the volumetrically bioprinted meniscus structures during the entire course of culture. However, the staining became more intense with time of differentiation, which suggested that chondrogenic differentiation successfully induced the additional secretion of cartilage-relevant ECM components. Since the limited vascularization in the native meniscus leads to poor self-regenerative capability, this VAM bioprinted meniscus provides a potential strategy for related biomedical applications for meniscus transplantation,[65] among other applications.
Our VAM-dECM system has indeed realized partial functionality in the bioprinted structures, such as the synchronized beating of hiPSC-CMs within h-dECM and the differentiation of hMSCs in Ms-dECM. Nonetheless, there are still substantial differences between these and native tissues in terms of structure, biology, and mechanics.[66] Native tissues consist of a complex array of cells, extracellular matrix, and signaling molecules, all arranged in specific architectures optimal for their functions,[67] whereas dECM is created by the decellularization process, which alters the ultrastructure potentially deviating from the tissue’s native mechanical properties and biological functionality to various extents.[25] Besides, native tissues possess inherent biological signals and a dynamic environment that support cell behaviors and tissue regeneration. dECM retains many of the signaling cues and growth factors from the original tissue, but the processing of decellularization may lead to a reduction or alteration of these components, which can influence cellular responses such as migration and differentiation.[25] For example, due to the decellularization process changing the structural features such as molecular arrangements, fiber alignments, and possible loss or denaturation of extracellular matrix proteins, a critical disparity is observed in the mechanical properties. The compressive modulus of native heart tissue ranges from 30-60 kPa[68] and that of the meniscus from 600-1,000 kPa,[69] whereas our bioprinted cardiac and meniscal structures approximated only 10 kPa each. All these differences, nevertheless, have provoked us with some directions for the future works: i) Including a multi-material bioprinting system to emulate more structurally relevant tissue structures with multiple tissue interfaces.[70] ii) Incorporating various cell types to establish a more realistic microenvironment, promoting extensive cell-cell interactions and diverse signaling pathways. iii) Integrating dECM with other biocompatible materials to enhance mechanical properties or cell-responsiveness without compromising the bioactivities of the dECM.[71, 72]
Conclusions
The potential for time-effective fabrication of hydrogel-based tissue constructs by VAM was demonstrated, using natural and unmodified dECM (bio)inks. With optimized formulations, both h-dECM and Ms-dECM showed significant print fidelity for sophisticated structures. Of interest, compared with the conventional layer-by-layer additive biomanufacturing methods, volumetric bioprinting was able to work with low-concentrations of dECM at a fast fabrication speed. Based on the favorable cytocompatibility of h-dECM and Ms-dECM, two proof-of-concept demonstrations of volumetrically bioprinted cardiac and meniscus constructs were illustrated. The spreading and contraction behaviors of rCMs and hiPSC-CMs encapsulated in the h-dECM heart-like constructs, as well as appropriate chondrogenic differentiation and gene expression of hMSCs embedded in the Ms-dECM meniscus constructs were demonstrated. In conclusion, this work explored a key biomaterial, i.e., dECM as (bio)inks for VAM, expanding the bioink library for this technology, while simultaneously broadening the applications of dECM-based biomaterials in biomedicine.
Supplementary Material
Acknowledgments
This work was performed in part at the Center for Nanoscale Systems (CNS), Harvard University, and supported by the National Institutes of Health (P41EB027062, R01AR070975, R01EB028143, R01HL165176, R01HL166522, R01CA282451, R21EB030257), the National Science Foundation award (1541959, CBET-EBMS-1936105, CISE-IIS-2225698), the ARO (W911NF2120130), the AFOSR (FA9550-20-1-0363), the Chan Zuckerberg Initiative (2022-316712), and the Brigham Research Institute.
Footnotes
Competing interests
YSZ consulted for Allevi by 3D Systems, and sits on the scientific advisory board and holds options of Xellar, neither of which however, participated in or biased the work.
Contributor Information
Liming Lian, Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Maobin Xie, Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Zeyu Luo, Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Zhenrui Zhang, Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA.
Sushila Maharjan, Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Xuan Mu, Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Carlos Ezio Garciamendez-Mijares, Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Xiao Kuang, Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Jugal Kishore Sahoo, Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA.
Guosheng Tang, Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Gang Li, Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA.
Di Wang, Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Jie Guo, Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Federico Zertuche González, Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Victoria Manjarrez, Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Ling Cai, Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Xuan Mei, Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
David L. Kaplan, Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA
Yu Shrike Zhang, Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
References
- [1].Murphy SV, Atala A, Nature Biotechnology 2014, 32, 773. [DOI] [PubMed] [Google Scholar]
- [2].Lian L, Zhou C, Tang G, Xie M, Wang Z, Luo Z, Japo J, Wang D, Zhou J, Wang M, Li W, Maharjan S, Ruelas M, Guo J, Wu X, Zhang YS, Advanced Healthcare Materials 2022, 11, 2102411. [DOI] [PubMed] [Google Scholar]
- [3].Wang D, Maharjan S, Kuang X, Wang Z, Mille LS, Tao M, Yu P, Cao X, Lian L, Lv L, He JJ, Tang G, Yuk H, Ozaki CK, Zhao X, Zhang YS, Science Advances, 8, eabq6900. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [4].Vargas AJ, Harris CC, Nature Reviews Cancer 2016, 16, 525. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [5].Heinrich MA, Liu W, Jimenez A, Yang J, Akpek A, Liu X, Pi Q, Mu X, Hu N, Schiffelers RM, Prakash J, Xie J, Zhang YS, Small 2019, 15, 1805510. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [6].Liu W, Zhong Z, Hu N, Zhou Y, Maggio L, Miri AK, Fragasso A, Jin X, Khademhosseini A, Zhang YS, Biofabrication 2018, 10, 024102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [7].Li X, Liu B, Pei B, Chen J, Zhou D, Peng J, Zhang X, Jia W, Xu T, Chemical Reviews 2020, 120, 10793. [DOI] [PubMed] [Google Scholar]
- [8].Liao J, Ye C, Guo J, Garciamendez-Mijares CE, Agrawal P, Kuang X, Japo JO, Wang Z, Mu X, Li W, Ching T, Mille LS, Zhu C, Zhang X, Gu Z, Zhang YS, Materials Today 2022, 56, 29. [Google Scholar]
- [9].You S, Guan J, Alido J, Hwang HH, Yu R, Kwe L, Su H, Chen S, Journal of Manufacturing Science and Engineering 2020, 142. [Google Scholar]
- [10].Bernal PN, Delrot P, Loterie D, Li Y, Malda J, Moser C, Levato R, Advanced Materials 2019, 31, 1904209. [DOI] [PubMed] [Google Scholar]
- [11].de Ruijter M, Ribeiro A, Dokter I, Castilho M, Malda J, Advanced Healthcare Materials 2019, 8, 1800418. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [12].Moroni L, Boland T, Burdick JA, De Maria C, Derby B, Forgacs G, Groll J, Li Q, Malda J, Mironov VA, Mota C, Nakamura M, Shu W, Takeuchi S, Woodfield TBF, Xu T, Yoo JJ, Vozzi G, Trends in Biotechnology 2018, 36, 384. [DOI] [PubMed] [Google Scholar]
- [13].Müller M, Öztürk E, Arlov Ø, Gatenholm P, Zenobi-Wong M, Annals of Biomedical Engineering 2017, 45, 210. [DOI] [PubMed] [Google Scholar]
- [14].Kelly BE, Bhattacharya I, Heidari H, Shusteff M, Spadaccini CM, Taylor HK, Science 2019, 363, 1075. [DOI] [PubMed] [Google Scholar]
- [15].Loterie D, Delrot P, Moser C, Nat Commun 2020, 11, 852. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [16].Jing S, Lian L, Hou Y, Li Z, Zheng Z, Li G, Tang G, Xie G, Xie M, Biofabrication 2023. [DOI] [PubMed] [Google Scholar]
- [17].Bernal PN, Bouwmeester M, Madrid-Wolff J, Falandt M, Florczak S, Rodriguez NG, Li Y, Größbacher G, Samsom R-A, van Wolferen M, van der Laan LJW, Delrot P, Loterie D, Malda J, Moser C, Spee B, Levato R, Advanced Materials 2022, 34, 2110054. [DOI] [PubMed] [Google Scholar]
- [18].Toombs JT, Luitz M, Cook CC, Jenne S, Li CC, Rapp BE, Kotz-Helmer F, Taylor HK, Science 2022, 376, 308. [DOI] [PubMed] [Google Scholar]
- [19].Tetsuka H, Shin SR, Journal of Materials Chemistry B 2020, 8, 2930. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [20].Rizzo R, Ruetsche D, Liu H, Zenobi-Wong M, Advanced Materials 2021, 33, 2102900. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [21].Xie M, Lian L, Mu X, Luo Z, Garciamendez-Mijares CE, Zhang Z, López A, Manríquez J, Kuang X, Wu J, Sahoo JK, González FZ, Li G, Tang G, Maharjan S, Guo J, Kaplan DL, Zhang YS, Nature Communications 2023, 14, 210. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [22].Kim H, Kang B, Cui X, Lee S-H, Lee K, Cho D-W, Hwang W, Woodfield TBF, Lim KS, Jang J, Advanced Functional Materials 2021, 31, 2011252. [Google Scholar]
- [23].Wolf MT, Daly KA, Brennan-Pierce EP, Johnson SA, Carruthers CA, D’Amore A, Nagarkar SP, Velankar SS, Badylak SF, Biomaterials 2012, 33, 7028. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [24].Mao Q, Wang Y, Li Y, Juengpanich S, Li W, Chen M, Yin J, Fu J, Cai X, Materials Science and Engineering: C 2020, 109, 110625. [DOI] [PubMed] [Google Scholar]
- [25].Zhang X, Chen X, Hong H, Hu R, Liu J, Liu C, Bioactive Materials 2022, 10, 15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [26].Zambon JP, Ko IK, Abolbashari M, Huling J, Clouse C, Kim TH, Smith C, Atala A, Yoo JJ, Acta Biomaterialia 2018, 75, 226. [DOI] [PubMed] [Google Scholar]
- [27].Potere F, Belgio B, Croci GA, Tabano S, Petrini P, Dubini G, Boschetti F, Mantero S, Frontiers in Bioengineering and Biotechnology 2022, 10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [28].Pati F, Jang J, Ha D-H, Won Kim S, Rhie J-W, Shim J-H, Kim D-H, Cho D-W, Nature Communications 2014, 5, 3935. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [29].Gao G, Lee JH, Jang J, Lee DH, Kong J-S, Kim BS, Choi Y-J, Jang WB, Hong YJ, Kwon S-M, Cho D-W, Advanced Functional Materials 2017, 27, 1700798. [Google Scholar]
- [30].Kim J, Shim IK, Hwang DG, Lee YN, Kim M, Kim H, Kim S-W, Lee S, Kim SC, Cho D-W, Jang J, Journal of Materials Chemistry B 2019, 7, 1773. [DOI] [PubMed] [Google Scholar]
- [31].Han W, Singh NK, Kim JJ, Kim H, Kim BS, Park JY, Jang J, Cho D-W, Biomaterials 2019, 224, 119496. [DOI] [PubMed] [Google Scholar]
- [32].Jang J, Park H-J, Kim S-W, Kim H, Park JY, Na SJ, Kim HJ, Park MN, Choi SH, Park SH, Kim SW, Kwon S-M, Kim P-J, Cho D-W, Biomaterials 2017, 112, 264. [DOI] [PubMed] [Google Scholar]
- [33].Kolesky DB, Homan KA, Skylar-Scott MA, Lewis JA, Proceedings of the National Academy of Sciences 2016, 113, 3179. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [34].Lee A, Hudson AR, Shiwarski DJ, Tashman JW, Hinton TJ, Yerneni S, Bliley JM, Campbell PG, Feinberg AW, Science 2019, 365, 482. [DOI] [PubMed] [Google Scholar]
- [35].Yu C, Ma X, Zhu W, Wang P, Miller KL, Stupin J, Koroleva-Maharajh A, Hairabedian A, Chen S, Biomaterials 2019, 194, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [36].Kolesky DB, Truby RL, Gladman AS, Busbee TA, Homan KA, Lewis JA, Advanced Materials 2014, 26, 3124. [DOI] [PubMed] [Google Scholar]
- [37].Gao G, Park JY, Kim BS, Jang J, Cho D-W, Advanced Healthcare Materials 2018, 7, 1801102. [DOI] [PubMed] [Google Scholar]
- [38].Kim W, Jang CH, Kim GH, Nano Letters 2019, 19, 8612. [DOI] [PubMed] [Google Scholar]
- [39].Gonen-Wadmany M, Goldshmid R, Seliktar D, Biomaterials 2011, 32, 6025. [DOI] [PubMed] [Google Scholar]
- [40].Lim KS, Schon BS, Mekhileri NV, Brown GCJ, Chia CM, Prabakar S, Hooper GJ, Woodfield TBF, ACS Biomaterials Science & Engineering 2016, 2, 1752. [DOI] [PubMed] [Google Scholar]
- [41].Bathish B, Paumann-Page M, Paton LN, Kettle AJ, Winterbourn CC, Journal of Biological Chemistry 2020, 295, 12697. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [42].Wang M, Li W, Hao J, Gonzales A, Zhao Z, Flores RS, Kuang X, Mu X, Ching T, Tang G, Luo Z, Garciamendez-Mijares CE, Sahoo JK, Wells MF, Niu G, Agrawal P, Quiñones-Hinojosa A, Eggan K, Zhang YS, Nature Communications 2022, 13, 3317. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [43].Lim KS, Klotz BJ, Lindberg GCJ, Melchels FPW, Hooper GJ, Malda J, Gawlitta D, Woodfield TBF, Macromolecular Bioscience 2019, 19, 1900098. [DOI] [PubMed] [Google Scholar]
- [44].Abaci A, Guvendiren M, Advanced healthcare materials 2020, 9, 2000734. [DOI] [PubMed] [Google Scholar]
- [45].Ma X, Yu C, Wang P, Xu W, Wan X, Lai CSE, Liu J, Koroleva-Maharajh A, Chen S, Biomaterials 2018, 185, 310. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [46].Li W, Wang M, Mille LS, Robledo Lara JA, Huerta V, Uribe Velázquez T, Cheng F, Li H, Gong J, Ching T, Murphy CA, Lesha A, Hassan S, Woodfield TBF, Lim KS, Zhang YS, Advanced Materials 2021, 33, 2102153. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [47].Perrone GS, Leisk GG, Lo TJ, Moreau JE, Haas DS, Papenburg BJ, Golden EB, Partlow BP, Fox SE, Ibrahim AMS, Lin SJ, Kaplan DL, Nature Communications 2014, 5, 3385. [DOI] [PubMed] [Google Scholar]
- [48].Pereira AR, Lipphaus A, Ergin M, Salehi S, Gehweiler D, Rudert M, Hansmann J, Herrmann M, in Materials, Vol. 14, 2021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [49].Makris EA, Hadidi P, Athanasiou KA, Biomaterials 2011, 32, 7411. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [50].Aye TT, Scholten A, Taouatas N, Varro A, Van Veen TAB, Vos MA, Heck AJR, Molecular BioSystems 2010, 6, 1917. [DOI] [PubMed] [Google Scholar]
- [51].Fox AJS, Bedi A, Rodeo SA, Sports Health 2012, 4, 340. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [52].Jang J, Kim TG, Kim BS, Kim S-W, Kwon S-M, Cho D-W, Acta Biomaterialia 2016, 33, 88. [DOI] [PubMed] [Google Scholar]
- [53].Ahn G, Min K-H, Kim C, Lee J-S, Kang D, Won J-Y, Cho D-W, Kim J-Y, Jin S, Yun W-S, Shim J-H, Scientific Reports 2017, 7, 8624. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [54].Elder BD, Eleswarapu SV, Athanasiou KA, Biomaterials 2009, 30, 3749. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [55].Wu J, Ding Q, Dutta A, Wang Y, Huang YH, Weng H, Tang L, Hong Y. [Google Scholar]
- [56].Wu J, Ding Q, Dutta A, Wang Y, Huang Y.-h., Weng H, Tang L, Hong Y, Acta Biomaterialia 2015, 16, 49. [DOI] [PubMed] [Google Scholar]
- [57].Xie M, Fan D, Li Y, He X, Chen X, Chen Y, Zhu J, Xu G, Wu X, Lan P, Int J Nanomedicine 2017, 12, 7751. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [58].Fitzpatrick V, Martin-Moldes Z, Deck A, Torres-Sanchez R, Valat A, Cairns D, Li C, Kaplan DL, Biomaterials 2021, 276, 120995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [59].Qi C, Liu J, Jin Y, Xu L, Wang G, Wang Z, Wang L, Biomaterials 2018, 163, 89. [DOI] [PubMed] [Google Scholar]
- [60].Bejleri D, Davis ME, Advanced healthcare materials 2019, 8, e1801217. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [61].Silbernagel N, Körner A, Balitzki J, Jaggy M, Bertels S, Richter B, Hippler M, Hellwig A, Hecker M, Bastmeyer M, Ullrich ND, Biomaterials 2020, 227, 119551. [DOI] [PubMed] [Google Scholar]
- [62].Karim A, Amin AK, Hall AC, Journal of Anatomy 2018, 232, 686. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [63].Visscher DO, Lee H, van Zuijlen PPM, Helder MN, Atala A, Yoo JJ, Lee SJ, Acta Biomaterialia 2021, 121, 193. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [64].Chae S, Lee S-S, Choi Y-J, Hong DH, Gao G, Wang JH, Cho D-W, Biomaterials 2021, 267, 120466. [DOI] [PubMed] [Google Scholar]
- [65].Makris EA, Hadidi P, Athanasiou KA, Biomaterials 2011, 32, 7411. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [66].Mameri ES, Dasari SP, Fortier LM, Verdejo FG, Gursoy S, Yanke AB, Chahla J, Current Reviews in Musculoskeletal Medicine 2022, 15, 323. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [67].Brown BN, Badylak SF, Translational Research 2014, 163, 268. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [68].Baghersad S, Sathish Kumar A, Kipper MJ, Popat K, Wang Z, in Journal of Functional Biomaterials, Vol. 14, 2023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [69].Morejon A, Norberg CD, De Rosa M, Best TM, Jackson AR, Travascio F, Frontiers in Bioengineering and Biotechnology 2021, 8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [70].Chae S, Yong U, Park W, Choi Y.-m., Jeon I-H, Kang H, Jang J, Choi HS, Cho D-W, Bioactive Materials 2023, 19, 611. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [71].Cui X, Li J, Hartanto Y, Durham M, Tang J, Zhang H, Hooper G, Lim K, Woodfield T, Advanced Healthcare Materials 2020, 9, 1901648. [DOI] [PubMed] [Google Scholar]
- [72].Ooi HW, Hafeez S, van Blitterswijk CA, Moroni L, Baker MB, Materials Horizons 2017, 4, 1020. [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.